The JAX Cancer Center offers comprehensive research support to members. Here you will find current federal and peer-reviewed foundation cancer-focused funding opportunities. If you have questions about any of these, please contact the Director of Research Program Development: Anna Lisa Lucido (email@example.com).
Notice of Intent to Publish a Funding Opportunity Announcement for Acquired Resistance to Therapy Network (ARTNet) (U54 Clinical Trial Not Allowed)
The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for Acquired Resistance to Therapy Network(ARTNet). The ARTNet FOA is a reissuance of RFA CA-17-009, which created a Drug Resistance and Sensitivity Network (DRSN) as part of the Cancer Moonshot initiative to accelerate clinical research on drug combinations.
For more information: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-063.html
The American Association of Cancer Research invites Letters of Intent for its AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants program. The program represents a joint effort to stimulate high-risk, high-reward research by early- to mid-career investigators (assistant or associate professors). The grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that might not be funded through conventional channels, and it is expected that the grants will catalyze significant scientific discoveries that advance the understanding of cancer and have a potentially transformative impact on future clinical practice. The research can be in any area of basic, translational, or clinical research.
Grants of up to $400,000 over two years will be awarded.
Letters of Intent are due June 29. Upon review, selected applicants will be invited to submit a full application by September 30.
For more information: https://www.aacr.org/grants/aacr-mpm-oncology-grants/
Dear Colleague Letter: Tool Development for Cell Biology (Tools4Cells). “Dear Colleague” letters at NSF are akin to the NIH Notice of Special Interest (NOSI). Here, NSF is encouraging the submission of proposals to develop novel tools and methods that “improve scientists' abilities to manipulate, control, analyze, or measure critical aspects of cells and their functions, in order to open new areas of study in cell biology”. Proposals should align with one of two programmatic divisions, depending on whether the tool/method would be applied to address a specific hypothesis or question and would be used by a small/defined user group (under this FOA); or would be applicable to a broad class of biological research questions/topics and would meet the needs of a well-defined community of researchers (under this FOA). Proposals are being accepted anytime under both FOAs.
Trans-NIAID Data Science Program FOAs. NIAID just released a group of FOAs that collectively aim to promote “research-driven data science technology across the development lifecycle to address priority needs in immune-mediated and infectious disease research”. The FOAs collectively cover all stages of data science tools/technology development: A R21 for exploratory methods development (up to $275K total direct costs for up to 2 years); a U01 for early-stage development (that builds on existing technology; up to $300K direct costs/year for up to 3 years); and a U24 mechanism for technology enhancement or sustainment of existing, widely used informatics resources (up to $600K/year for up to 5 years). Deadlines: Multiple over the next two years. Next deadline is July 2, 2021.
Development of Animal Models and Related Biological Materials for Research (R21):This is a re-issued PAR that solicits projects to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems and must have broad application to multiple NIH institutes or centers. This PAR will be open for 3 years, operates by standard deadlines (June/Oct/Feb 16) and standard budget thresholds (up to $275K total direct costs over 2 years).